V. CLAIMS

What is claimed is:

1. Use of NK cells and an anti-PDL1 antibody in the manufacture of a medicament for treating a cancer in a subject.
2. The use of claim 1, wherein the NK cells are XM NK cells.
3. The use of claim 1, wherein the NK cells are activated or expanded by contacting a naive NK cell population with PM21 particles, EX21 exosomes, or FC21 feeder cells.
4. The use of claim 3, wherein the activation or expansion of NK cells by PM21 particles, EX21 exosomes, or FC21 cells occurs ex vivo.
5. The use of claim 4, wherein the activation of expansion of NK cells by PM21 particles, EX21 exosomes, or FC21 cells occurs between 1 and 21 days prior to the administration of the NK cells to the subject.
6. The use of claim 1, wherein the NK cells may be derived from peripheral blood umbilical cord blood, or stem cells.
7. The use of claim 1, wherein the NK cells are from a NK cell like cell line such as NK92.
8. The use of claim 1, wherein the NK cells are to be administered between 1 and 14 days prior to administration of the anti-PDL1 antibody.
9. The use of claim 1, wherein the NK cells and anti-PDL1 antibody are to be administered concurrently.
10. The use of claim 1, wherein the NK cells are autologous, haploidentical, or allogeneic NK cells.
11. The use of claim 1, further comprising contacting the NK cells with one or more of IL-12, IL-15, and IL-18 prior to administration of the NK cells to the subject.
12. The use of claim 1, wherein one or more of IL-12, IL-15, and IL-18 is to be administered to the subject.
13. The use of claim 12, wherein the IL-12, IL-15, and IL-18 are to be administered concurrently with the NK cells.
14. The use of claim 12, wherein the IL-12, IL-15, and IL-18 are to be administered prior to administration of the NK cells.

15. The use of claim 12, wherein the IL-12, IL-15, and IL-18 are to be administered following administration of the NK cells.

16. The use of claim 1, wherein PM21 particles or EX21 exosomes are to be administered to the subject.

17. The use of claim 16, wherein the PM21 particles or EX21 exosomes are to be administered concurrently with the NK cells.

18. The use of claim 16, wherein the PM21 particles or EX21 exosomes are to be administered at least 1, 2, 3 times per week following the administration of the NK cells.

19. Use of PM21 particles or EX21 exosomes and an anti-PDL1 antibody in the manufacture of a medicament for treating a cancer in a subject.

20. The use of claim 19, wherein the PM21 particles or EX21 exosomes are to be administered between 1 and 14 days prior to administration of the anti-PDL1 antibody.

21. The use of claim 19, wherein the PM21 particles or EX21 exosomes and the anti-PDL1 antibody are to be administered concurrently.

22. The use of claim 19, wherein one or more of IL-12, IL-15, and IL-18 is to be administered to the subject.

23. The use of claim 22, wherein the IL-12, IL-15, and IL-18 are to be administered concurrently with the PM21 particles or EX21 exosomes.

24. The use of claim 22, wherein the IL-12, IL-15, and IL-18 are to be administered prior to administration of the PM21 particles or EX21 exosomes.

25. The use of claim 22, wherein the IL-12, IL-15, and IL-18 are to be administered following administration of the PM21 particles or EX21 exosomes.

26. The use of claim 19, wherein the PM21 particles or EX21 exosomes are to be administered at least 1, 2, 3 times per week following the initial administration of PM21 particles or EX21 exosomes.

27. Use of PM21, EX21, or FC21 NK cells and an anti-PDL1 antibody in the manufacture of a medicament for anti-cancer therapy.

28. The use of claim 27, further comprising PM21 particles or EX21 exosomes.

29. The use of claim 27, further comprising one or more of IL-12, IL-15, and IL-18.

30. Use of PM21 particles or EX21 exosomes and an anti-PDL1 antibody in the manufacture of a medicament for anti-cancer therapy.

31. The use of claim 30, further comprising one or more of IL-12, IL-15, and IL-18.